INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data : vimarsana.com

Oral presentation delivered at the American Heart Association (AHA) Scientific Sessions 2023 Analysis of clinical data shows statistically significant risk reductions in heart failure and separately in MACE related outcomes as early as approximately three months in patients at high risk for cardiovascular events INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure THE WOODLANDS, Texas, Nov. 12, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today

Related Keywords

Pennsylvania , United States , Philadelphia , Boston , Massachusetts , Texas , American , Rahul Aggarwal , Craig Granowitz , Exchange Commission , Lexicon Pharmaceuticals , Lexicon Pharmaceuticals Inc , Drug Administration , Science Session Of The American Heart Association , Nasdaq , American Heart Association , Scientific Sessions , Concomitant Use , Insulin Secretagogues , Mycotic Infections , Glucose Test , Adverse Reactions , Specific Populations , Late Breaking Science Session , New England Journal , Chronic Kidney Disease , Investor Inquiries , Relative Risk Reduction , Eart Failure , Cardiovascular Events , Sotagliflozin , Npefa , Merican Heart Association , Post Hoc Analysis , Cardiovascular Death , Hronic Kidney Disease , Primary Endpoint , Iabetes Mellitus , Ospitalization ,